147 related articles for article (PubMed ID: 10895062)
21. [The efficacy and toxicity of gemcitabine and cisplatin chemotherapy in advanced/metastatic bladder urothelial carcinoma].
Gunlusoy B; Arslan M; Vardar E; Degirmenci T; Kara C; Ceylan Y; Kozacıoğlu Z
Actas Urol Esp; 2012 Oct; 36(9):515-20. PubMed ID: 22819345
[TBL] [Abstract][Full Text] [Related]
22. Gemcitabine plus carboplatin; and gemcitabine, docetaxel, and carboplatin combined chemotherapy regimens in patients with metastatic urothelial carcinoma previously treated with a platinum-based regimen: preliminary report.
Hoshi S; Ohyama C; Ono K; Takeda A; Yamashita S; Yamato T; Itoh A; Satoh M; Saito S; Okada Y; Sohma F; Arai Y
Int J Clin Oncol; 2004 Apr; 9(2):125-9. PubMed ID: 15108045
[TBL] [Abstract][Full Text] [Related]
23. A phase II study of gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the bladder.
Eroglu Z; Fruehauf JP
Cancer Chemother Pharmacol; 2013 Jul; 72(1):263-7. PubMed ID: 23636451
[TBL] [Abstract][Full Text] [Related]
24. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial.
Dogliotti L; Cartenì G; Siena S; Bertetto O; Martoni A; Bono A; Amadori D; Onat H; Marini L
Eur Urol; 2007 Jul; 52(1):134-41. PubMed ID: 17207911
[TBL] [Abstract][Full Text] [Related]
25. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
Shelley M; Cleves A; Wilt TJ; Mason M
Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
[TBL] [Abstract][Full Text] [Related]
26. Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder.
Smith DC; Mackler NJ; Dunn RL; Hussain M; Wood D; Lee CT; Sanda M; Vaishampayan U; Petrylak DP; Quinn DI; Beekman K; Montie JE
J Urol; 2008 Dec; 180(6):2384-8; discussion 2388. PubMed ID: 18930256
[TBL] [Abstract][Full Text] [Related]
27. The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group.
Bamias A; Moulopoulos LA; Koutras A; Aravantinos G; Fountzilas G; Pectasides D; Kastritis E; Gika D; Skarlos D; Linardou H; Kalofonos HP; Dimopoulos MA
Cancer; 2006 Jan; 106(2):297-303. PubMed ID: 16342065
[TBL] [Abstract][Full Text] [Related]
28. Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer.
Carles J; Esteban E; Climent M; Font A; Gonzalez-Larriba JL; Berrocal A; Garcia-Ribas I; Marfa X; Fabregat X; Albanell J; Bellmunt J;
Ann Oncol; 2007 Aug; 18(8):1359-62. PubMed ID: 17693649
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer.
Iwasaki K; Obara W; Kato Y; Takata R; Tanji S; Fujioka T
Jpn J Clin Oncol; 2013 Feb; 43(2):193-9. PubMed ID: 23275643
[TBL] [Abstract][Full Text] [Related]
30. Our experience with 23 consecutive patients on gemcitabine/carboplatin chemotherapy for treatment of metastasized transitional cell carcinoma of the urothelium.
Hoschke B; May M; Seehafer M; Helke C
Int J Urol; 2004 Jul; 11(7):461-6. PubMed ID: 15242353
[TBL] [Abstract][Full Text] [Related]
31. Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99).
Fechner G; Siener R; Reimann M; Kobalz L; Albers P;
Int J Clin Pract; 2006 Jan; 60(1):27-31. PubMed ID: 16409425
[TBL] [Abstract][Full Text] [Related]
32. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network.
Meluch AA; Greco FA; Burris HA; O'Rourke T; Ortega G; Steis RG; Morrissey LH; Johnson V; Hainsworth JD
J Clin Oncol; 2001 Jun; 19(12):3018-24. PubMed ID: 11408496
[TBL] [Abstract][Full Text] [Related]
33. A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer.
Hussain SA; Stocken DD; Riley P; Palmer DH; Peake DR; Geh JI; Spooner D; James ND
Br J Cancer; 2004 Aug; 91(5):844-9. PubMed ID: 15292922
[TBL] [Abstract][Full Text] [Related]
34. Multicenter Phase 2 Trial of Gemcitabine, Carboplatin, and Sorafenib in Patients With Metastatic or Unresectable Transitional-Cell Carcinoma.
Hurwitz ME; Markowski P; Yao X; Deshpande H; Patel J; Mortazavi A; Donadio A; Stein MN; Kelly WK; Petrylak DP; Mehnert JM
Clin Genitourin Cancer; 2018 Dec; 16(6):437-444.e6. PubMed ID: 30177237
[TBL] [Abstract][Full Text] [Related]
35. A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder.
Grivas PD; Hussain M; Hafez K; Daignault-Newton S; Wood D; Lee CT; Weizer A; Montie JE; Hollenbeck B; Montgomery JS; Alva A; Smith DC
Urology; 2013 Jul; 82(1):111-7. PubMed ID: 23706253
[TBL] [Abstract][Full Text] [Related]
36. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study.
Li J; Juliar B; Yiannoutsos C; Ansari R; Fox E; Fisch MJ; Einhorn LH; Sweeney CJ
J Clin Oncol; 2005 Feb; 23(6):1185-91. PubMed ID: 15718315
[TBL] [Abstract][Full Text] [Related]
37. Sequential chemotherapy using gemcitabine + carboplatin followed by gemcitabine + carboplatin + docetaxel for advanced upper-tract urothelial cancer.
Yoneyama T; Imai A; Hatakeyama S; Hashimoto Y; Koie T; Ohyama C
Int J Clin Oncol; 2015 Dec; 20(6):1179-84. PubMed ID: 26007690
[TBL] [Abstract][Full Text] [Related]
38. Combination chemotherapy of carboplatin and gemcitabine against solid tumors: a phase I trial.
Tassinari D; Drudi G; Panzini I; Pasini G; Arcangeli V; Fochessati F; Gianni L; Mianulli AM; Oliverio G; Pasquini E; Sartori S; Ravaioli A
Int J Clin Oncol; 2001 Dec; 6(6):279-83. PubMed ID: 11828946
[TBL] [Abstract][Full Text] [Related]
39. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.
Bellmunt J; Guillem V; Paz-Ares L; González-Larriba JL; Carles J; Batiste-Alentorn E; Sáenz A; López-Brea M; Font A; Nogué M; Bastús R; Climent MA; de la Cruz JJ; Albanell J; Banús JM; Gallardo E; Diaz-Rubio E; Cortés-Funes H; Baselga J
J Clin Oncol; 2000 Sep; 18(18):3247-55. PubMed ID: 10986057
[TBL] [Abstract][Full Text] [Related]
40. Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
Gray HJ; Bell-McGuinn K; Fleming GF; Cristea M; Xiong H; Sullivan D; Luo Y; McKee MD; Munasinghe W; Martin LP
Gynecol Oncol; 2018 Mar; 148(3):507-514. PubMed ID: 29352572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
